GlaxoSmithKline plc (LON:GSK) said the positive results from its study of asthma treatment, Relvar Eillipta, has been published in The Lancet medical journal and presented at the European Respiratory Society International Congress in Milan.
The Salford Lung Study, which reported headline results in May, showed that initiation of once-daily Relvar Eillipta was superior to usual care medicines in achieving a consistent improvement in patient’s asthma over 12 months.
GSK said at 24 weeks, 71% of patients with symptomatic asthma treated with Relvar Eillipta had better control of their asthma, compared with 56% of those continuing usual care treatments, including inhaled corticosteroids (ICS) administered as monotherapy or as ICS/LABA (long acting beta agonist) combinations.
Secondary analyses showed that patients also achieved higher quality of life scores and lower impact on their ability to work and take part in activities.
"Living with asthma can have a significant effect on people's day to day life, from sleeping well at night, to doing exercise, and going to work or school,” said Ashley Woodcock, lead investigator and professor of respiratory medicine and clinical director for respiratory medicine at the University Hospital of South Manchester and University of Manchester.
“Unfortunately, people with asthma often don't realise improvements can be made to these parts of their lives. That's why research, such as the Salford Lung Studies, are important tools to help the medical community manage asthma in a way that has a positive impact for people living with this debilitating condition. We're delighted the Lancet has published the results of what I believe to be a pioneering study."
Shares in GSK dipped 0.23% to 1,490p in afternoon trading.